新生血管性年龄相关性黄斑变性进展为晚期中心性新生血管后由主动治疗转为按需治疗的结果
基于前瞻性设计的多国真实世界登记数据的回顾性分析,评估新生血管性年龄相关性黄斑变性眼在出现黄斑萎缩或黄斑下纤维化后由主动治疗(治疗并延长)转为按需治疗的结果。黄斑萎缩821眼、黄斑下纤维化1166眼,分别有7%和9%转为按需治疗。黄斑萎缩及非活动性黄斑下纤维化眼12个月视力稳定;活动性黄斑下纤维化眼转为按需治疗后视力显著下降。
要点
- 黄斑萎缩821眼、黄斑下纤维化1166眼,分别7%和9%转为按需治疗。
- 黄斑萎缩和非活动性黄斑下纤维化眼转按需治疗后12个月视力稳定。
- 活动性黄斑下纤维化眼转按需治疗后出现显著视力下降,8%转按需眼和15%活动性黄斑下纤维化眼视力下降≥15个字母。
核心结论
- 出现黄斑萎缩和非活动性黄斑下纤维化后由主动治疗转为按需治疗的眼可有稳定的视力结局。
- 医生应知晓活动性黄斑下纤维化眼转为按需治疗后存在显著视力下降的风险。
研究设计与样本
- 对前瞻性设计的多国真实世界新生血管性年龄相关性黄斑变性治疗结局登记数据进行回顾性分析。
- 纳入开始血管内皮生长因子抑制剂治疗时无黄斑萎缩或黄斑下纤维化、随后出现黄斑萎缩或黄斑下纤维化的眼。
- 黄斑萎缩821眼,黄斑下纤维化1166眼。
主要发现
- 出现黄斑萎缩的眼中有7%转为按需治疗,出现黄斑下纤维化的眼中有9%转为按需治疗。
- 所有黄斑萎缩眼和非活动性黄斑下纤维化眼在12个月时视力稳定。
- 转为按需治疗的活动性黄斑下纤维化眼出现显著视力下降。
- 继续主动治疗的眼无一例出现≥15个字母视力下降,而所有转为按需治疗的眼中有8%、活动性黄斑下纤维化眼中有15%出现≥15个字母视力下降。
临床怎么用
- 作者认为,出现黄斑萎缩和非活动性黄斑下纤维化后由主动治疗转为按需治疗的眼可有稳定的视力结局。
- 作者提醒医生应知晓活动性黄斑下纤维化眼转为按需治疗后存在显著视力下降的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed outcomes of eyes with neovascular age-related macular degeneration (nAMD) that switched from proactive (treat-and-extend) to reactive (pro re nata) treatment regimen after developing macular atrophy (MA) or submacular fibrosis (SMFi). METHODS: Data were collected from a retrospective analysis of a prospectively designed, multinational registry of "real-world" nAMD treatment outcomes. Eyes without MA or SMFi when starting treatment with a vascular endothelial growth factor inhibitor regimen that subsequently developed MA or SMFi were included. RESULTS: Macular atrophy developed in 821 eyes and SMFi in 1,166 eyes. Seven percent of eyes that developed MA and 9% of those that developed SMFi were switched to reactive treatment. Vision was stable at 12 months for all eyes with MA and inactive SMFi. Active SMFi eyes that switched to reactive treatment had significant vision loss. No eyes that continued proactive treatment developed ≥15 letter loss, but 8% of all eyes that switched to a reactive regimen and 15% of active SMFi eyes did. CONCLUSION: Eyes that switch from proactive to reactive treatment after developing MA and inactive SMFi can have stable visual outcomes. Physicians should be aware of the risk of a significant loss of vision in eyes with active SMFi that switch to reactive treatment.
引用
- Cornish EE, Nguyen V, Puzo M, et al. OUTCOMES OF SWITCHING FROM PROACTIVE TO REACTIVE TREATMENT AFTER DEVELOPING ADVANCED CENTRAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2023. PMID: 36893432. doi:10.1097/IAE.0000000000003771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。